View Financial HealthEli Lilly 배당 및 자사주 매입배당 기준 점검 3/6Eli Lilly 수익으로 충분히 충당되는 현재 수익률 0.72% 보유한 배당금 지급 회사입니다.핵심 정보0.7%배당 수익률0.5%자사주 매입 수익률총 주주 수익률1.2%미래 배당 수익률0.9%배당 성장률11.8%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향22%최근 배당 및 자사주 매입 업데이트Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025Jun 24Eli Lilly and Company Declares Dividend for the Second Quarter of 2025, Payable on June 10, 2025May 06모든 업데이트 보기Recent updatesEli Lilly and Company Raises Earning Guidance for the Year 2026May 03Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.Apr 27Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 BillionApr 21+ 1 more updateEli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular RiskApr 17+ 1 more updateEli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire CrossBridge Bio, Inc. from Portal Innovations, LLC, The Texas Medical Center Venture Fund, Alexandria Venture Investments, LLC, Linden Lake Venture Capital, Cancer Prevention and Research Institute of Texas and Crescent Enterprises Venture Capital for $300 million.Apr 16Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLLApr 14Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.SApr 09Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight LossApr 01Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.Mar 31Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and ObesityMar 30Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic DermatitisMar 27Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 DiabetesMar 19Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic DermatitisMar 16Eli Lilly and Company, Annual General Meeting, May 04, 2026Mar 09Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding ActosMar 07Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage OptionsMar 05+ 1 more updateEli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia AreataFeb 27Eli Lilly and Company Announces Detailed Results from ACHIEVE-3Feb 26Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)Feb 23Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)Feb 20Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)Feb 18Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of RetevmoFeb 16Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.Feb 09Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026Feb 04Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026Jan 21Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian CancerJan 20Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo NordiskJan 15Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)Jan 09Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.Jan 08Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli LillyJan 07Now 21% undervalued Jan 05Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).Jan 02Insufficient new directors Dec 30Eli Lilly and Company Announces Oral GLP-1 OrforglipronDec 20Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trialDec 18Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast CancerDec 13Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical TrialDec 11Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)Dec 09+ 2 more updatesEli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)Dec 04Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli LillyNov 26Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual MeetingNov 25+ 1 more updateEli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025Nov 22Eli Lilly and Company Announces Management AppointmentsNov 07Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of EloralintideNov 06Eli Lilly and Company Raises Earnings Guidance for the Year 2025Oct 30Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative ColitisOct 28+ 1 more updateEli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative ColitisOct 27Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.Oct 24+ 1 more updateEli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche TrialOct 17Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025Oct 16Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 TrialsOct 15Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule DiscoveryOct 09Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four YearsOct 07Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast CancerSep 26+ 1 more updateEli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of MounjaroSep 18Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3Sep 17+ 1 more updateEli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research InvestmentSep 09Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of JaypircaSep 08Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung CancerSep 04Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE TrialAug 27Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 TrialAug 26Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025Aug 20Chairman recently bought €901k worth of stock Aug 19Ken Paxton Files Lawsuit in State Court Against Eli Lilly and CoAug 15Eli Lilly and Company Raises Earning Guidance for the Year 2025Aug 07+ 1 more updateEli Lilly and Company Announces Topline Results from SURPASS-CVOTJul 31Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 StudyJul 30Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of JaypircaJul 29Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's DiseaseJul 25Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025Jul 24Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's DiseaseJul 09Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025Jun 24Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora AlfaJun 23Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise AloneJun 22Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli LillyJun 19Lilly to Offer All Approve Doses of Zepbound (Tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy SolutionsJun 18Eli Lilly Reportedly Nears $1.3 Billion Deal for Verve TherapeuticsJun 17Eli Lilly and Company Presents First Clinical Data for Its Investigational, Next-Generation Fra Targeting Adc in Platinum-Resistant Ovarian Cancer At the 2025 Asco Annual MeetingJun 03Eli Lilly and Company (NYSE:LLY) agreed to acquire SiteOne Therapeutics, Inc. for $1 billion.May 27Eli Lilly and Company Announces Details of Presentation at 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23Eli Lilly and Company Receives Marketing Authorization in Australia for the Treatment of Early Symptomatic Alzheimer's DiseaseMay 22Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of MedicineMay 12Eli Lilly and Company, Lilly Cardiometabolic Health and Lilly Usa, Llc Announces Executive AppointmentsMay 08Eli Lilly and Company Declares Dividend for the Second Quarter of 2025, Payable on June 10, 2025May 06AMRA Medical Announces Latest Data from SURPASS-3 Trial Gleans Insight into the Association of Tirzepatide Treatment with Changes in Muscle Composition in Type 2 DiabetesMay 02Eli Lilly and Company Reaffirms Earnings Guidance for the Year 2025May 01Eli Lilly and Company to Report Q1, 2025 Results on May 01, 2025Apr 17+ 1 more update지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: LLY 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: LLY 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Eli Lilly 배당 수익률 vs 시장LLY의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LLY)0.7%시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.5%업계 평균 (Pharmaceuticals)2.8%분석가 예측 (LLY) (최대 3년)0.9%주목할만한 배당금: LLY 의 배당금( 0.72% )은 German 시장에서 배당금 지급자의 하위 25%( 1.57% )와 비교해 주목할 만하지 않습니다.고배당: LLY 의 배당금( 0.72% )은 German 시장에서 배당금 지급자의 상위 25%( 4.51% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 22.1% )이 낮기 때문에 LLY 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 99.8% )이 높기 때문에 LLY 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 20:56종가2026/04/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Eli Lilly and Company는 53명의 분석가가 다루고 있습니다. 이 중 27명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David ToungArgus Research CompanyEmily FieldBarclaysKerry HolfordBerenberg50명의 분석가 더 보기
Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025Jun 24
Eli Lilly and Company Declares Dividend for the Second Quarter of 2025, Payable on June 10, 2025May 06
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.Apr 27
Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 BillionApr 21+ 1 more update
Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular RiskApr 17+ 1 more update
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire CrossBridge Bio, Inc. from Portal Innovations, LLC, The Texas Medical Center Venture Fund, Alexandria Venture Investments, LLC, Linden Lake Venture Capital, Cancer Prevention and Research Institute of Texas and Crescent Enterprises Venture Capital for $300 million.Apr 16
Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLLApr 14
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.SApr 09
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.Mar 31
Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and ObesityMar 30
Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic DermatitisMar 27
Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 DiabetesMar 19
Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic DermatitisMar 16
Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding ActosMar 07
Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage OptionsMar 05+ 1 more update
Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia AreataFeb 27
Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)Feb 23
Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)Feb 20
Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)Feb 18
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of RetevmoFeb 16
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.Feb 09
Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian CancerJan 20
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo NordiskJan 15
Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)Jan 09
Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.Jan 08
Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).Jan 02
Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast CancerDec 13
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical TrialDec 11
Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)Dec 09+ 2 more updates
Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)Dec 04
Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual MeetingNov 25+ 1 more update
Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025Nov 22
Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of EloralintideNov 06
Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative ColitisOct 28+ 1 more update
Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative ColitisOct 27
Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.Oct 24+ 1 more update
Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche TrialOct 17
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 TrialsOct 15
Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule DiscoveryOct 09
Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four YearsOct 07
Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast CancerSep 26+ 1 more update
Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of MounjaroSep 18
Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research InvestmentSep 09
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of JaypircaSep 08
Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung CancerSep 04
Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE TrialAug 27
Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025Aug 20
Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 StudyJul 30
Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of JaypircaJul 29
Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's DiseaseJul 25
Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's DiseaseJul 09
Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025Jun 24
Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora AlfaJun 23
Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise AloneJun 22
Lilly to Offer All Approve Doses of Zepbound (Tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy SolutionsJun 18
Eli Lilly and Company Presents First Clinical Data for Its Investigational, Next-Generation Fra Targeting Adc in Platinum-Resistant Ovarian Cancer At the 2025 Asco Annual MeetingJun 03
Eli Lilly and Company Announces Details of Presentation at 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23
Eli Lilly and Company Receives Marketing Authorization in Australia for the Treatment of Early Symptomatic Alzheimer's DiseaseMay 22
Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of MedicineMay 12
Eli Lilly and Company, Lilly Cardiometabolic Health and Lilly Usa, Llc Announces Executive AppointmentsMay 08
Eli Lilly and Company Declares Dividend for the Second Quarter of 2025, Payable on June 10, 2025May 06
AMRA Medical Announces Latest Data from SURPASS-3 Trial Gleans Insight into the Association of Tirzepatide Treatment with Changes in Muscle Composition in Type 2 DiabetesMay 02